Back to News
Oct 28, 2025 4:00 AM

Samsung Biologics reports third quarter 2025 financial results

Recorded Q3'25 consolidated revenue of KRW 1,660.2 billion

Recorded Q3'25 consolidated operating profit of KRW 728.8 billion

Delivered consistent performance through stable capacity ramp-up and strengthened global partnerships

INCHEON, South Korea, Oct. 28, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the third quarter of fiscal year 2025.

"Our third quarter results reflect the solid foundation we have built through operational excellence and disciplined execution," said John Rim, CEO and President of Samsung Biologics. "We continue to prioritize standardization and scalability across our global network under our ExellenS™ manufacturing framework, delivering speed, reliability, and predictable outcomes that our partners can count on. As the industry evolves, our commitment remains clear—to create sustained value for clients by ensuring that every product we manufacture contributes to advancing patient health worldwide."

THIRD QUARTER 2025 RESULTS

Samsung Biologics posted consolidated revenue of KRW 1,660.2 billion and operating profit of KRW 728.8 billion in the third quarter of 2025, driven by full-scale operations at Plant 4 and steady sales across all business ...